The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
ORGANIZATION
Discuss Cost Effectiveness Assessment, Disclosure Ratios Separately: FPMAJ
Japan’s cost-effectiveness assessment (CEA) scheme introduced in April not only targets products granted launch premiums but also cuts into non-granted ones depending on the ratio of manufacturing cost disclosures. The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) reiterated its…
To read the full story
Related Article
- Generic Share Hits Plateau after Reaching 70%: FPMAJ Pharmacy Survey
June 17, 2019
- Japan to Roll Out Cost-Effectiveness Assessment Scheme in April
February 21, 2019
- MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
ORGANIZATION
- Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
- Expand Self-Medication Tax Break to Cover All Non-Prescription Drugs: OTC Group
July 6, 2020
- Stop Patient Enrollment in Avigan Studies: Drug Damage Watchdog
July 3, 2020
- Drug Makers Joining Forces to Share Manufacturing Capacities, Accelerate COVID-19 Programs: PhRMA CMO
July 2, 2020
- COVID-19 Having “Serious Impact” on New Drug Development; JPMA Calls for Strong Systems for Emergencies
July 2, 2020
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…